glp-1 liver Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Disease: A Clinical Perspective GLP-1 Receptor Agonists as Treatments

GLP-1 RAs in the treatment of T2DM and weight loss effects GLP-1 RAs were licensed for the treatment of T2DM due to their ability to lower A1C and achieve the hemoglobin A1c (HbA1c) goal of 48 mmol/mol (6.5%), a history of type 1 or T2D, or evidence of a previous MI, stroke, hospitalization for unstable angina pectoris, or transient ischemic attack within 60 days of screening are excluded

But there was one unexpected downside

doi: 10.1016/j.mce.2015.02.014

VAT/1szt.(0,13 / pc

Larger and more diverse patient cohorts are needed, lower dosages of semaglutide have to be tested, and follow-ups need to be conducted beyond 26 weeks.